Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $7.659 million which missed the analyst consensus estimate of $13.904 million by 44.92 percent. This is a 46.23 percent decrease over sales of $14.245 million the same period last year.